COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,672 Articles (22,913 medRxiv, 8,759 bioRxiv)

Most recent first Previous |  Page 699: Articles 6981-6990  | Next

Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination
Almadhi, M., AlAwadhi, A., Stevenson, N., Greish, K., Jawad, J., Alsayyad, A., Mirza, A., Alsaffar, B., AlAlawi, E., Fakhroo, K., AlAlawi, B., Alabbasi, L., Aljalahma, N., AlQahtani, M.
10.1101/2022.08.24.22279160 — Posted: 2022-08-24
New Insights into How JUUL Electronic Cigarette Aerosols and Aerosol Constituents Affect SARS-CoV-2 Infection of Human Bronchial Epithelial Cells
Phandthong, R., Wong, M., Song, A., Martinez, T., Talbot, P.
10.1101/2022.08.23.505031 — Posted: 2022-08-24
Integrated Immunopeptidomics and Proteomics Study Reveals Imbalanced Innate and Adaptive Immune Responses to SARS-Cov-2 Infection
Chen, R., Fulton, K. M., Tran, A., Duque, D., Kovalchik, K., Caron, E., Twine, S. M., Li, J.
10.1101/2022.08.23.504798 — Posted: 2022-08-24
A Deep Learning Approach to Forecast Short-Term COVID-19 Cases and Deaths in the US
Du, H., Dong, E., Badr, H. S., Petrone, M., Grubaugh, N., Gardner, L. M.
10.1101/2022.08.23.22279132 — Posted: 2022-08-24
Post-COVID syndrome prevalence and risk factors in children and adolescents: A population-based serological study
Dumont, R., Richard, V., Lorthe, E., Loizeau, A., BAYSSON, H. H., Pennacchio, F., Zaballa, M. E., Nehme, M., Perrin, A., L'Huillier, A. H., Kaiser, L., Barbe, R., Posfay Barbe, K., Stringhini, S., Guessous, I.
10.1101/2022.08.24.22279150 — Posted: 2022-08-24
Effective Matrix Designs for COVID-19 Group Testing
Brust, D., Brust, J. J.
10.1101/2022.08.23.22279137 — Posted: 2022-08-24
Public health interventions successfully mitigated multiple incursions of SARS-CoV-2 Delta variant in the Australian Capital Territory
Hall, R. N., Jones, A., Crean, E., Marriott, V., Pingault, N., Marmor, A., Sloan-Gardner, T., Kennedy, K., Coleman, K., Johnston, V., Schwessinger, B.
10.1101/2022.08.23.22278828 — Posted: 2022-08-24
The Impact of SARS-CoV-2 Vaccine Dose Separation and Dose Targeting on Hospital Admissions and Deaths from COVID-19 in England
Keeling, M. J., Penman, B., Hill, E. M., Moore, S.
10.1101/2022.08.22.22278973 — Posted: 2022-08-24
Data-Driven Design of Protein-Derived Peptide Multiplexes for Biomimetic Detection of Exhaled Breath VOC Profiles
Nakano-Baker, O., Fong, H., Shukla, S., Lee, R., Cai, L., Godin, D., Hennig, T., Rath, S. S., Novosselov, I., Dogan, S., Sarikaya, M., MacKenzie, J. D.
10.1101/2022.08.23.504912 — Posted: 2022-08-23
Mucosal gene expression in response to SARS-CoV-2 is associated with early viral load.
Rajagopala, S. V., Strickland, B. A., Pakala, S. B., Kimura, K. S., Shilts, M. H., Rosas-Salazar, C., Brown, H. M., Freeman, M. H., Wessinger, B. C., Gupta, V., Phillips, E., Mallal, S. A., Turner, J. H., Das, S. R.
10.1101/2022.08.23.504908 — Posted: 2022-08-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).